Correlation of adverse effects of cisplatin administration in patients affected by solid tumours: A retrospective evaluation

Astolfi,Laura; Ghiselli,Sara; Guaran,Valeria; Chicca,Milvia; Simoni,Edi; Olivetto,Elena; Lelli,Giorgio; Martini,Alessandro

doi:10.3892/or.2013.2279

Correlation of adverse effects of cisplatin administration in patients affected by solid tumours: A retrospective evaluation

Authors:
- Laura Astolfi
- Sara Ghiselli
- Valeria Guaran
- Milvia Chicca
- Edi Simoni
- Elena Olivetto
- Giorgio Lelli
- Alessandro Martini
View Affiliations

Affiliations: Bioacoustics Research Laboratory, University of Padua, I-35129 Padua, Italy, ENT Surgery, Department of Neurosciences, University of Padua, I-35129 Padua, Italy, Department of Life Sciences and Biotechnology, University of Ferrara, I-44121 Ferrara, Italy, Clinical Oncology Unit, St. Anna University-Hospital, I-44121 Ferrara, Italy
Published online on: February 6, 2013 https://doi.org/10.3892/or.2013.2279
Pages: 1285-1292
Copyright: © Astolfi et al. This is an open access article distributed under the terms of Creative Commons Attribution License [CC BY_NC 3.0].

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Cisplatin is the most common antineoplastic drug used for the therapy of solid tumours. To date, researchers have focused on the dosage to be administered for each specific tumour, mainly considering the local adverse effects. The aim of this study was to correlate the severity of the adverse effects with: i) the dosage of cisplatin; ii) the specific site of the tumour; iii) the association with other drugs; and iv) the symptoms. We analysed data from 123 patients with 11 different tumour classes undergoing therapy from 2007 to 2008 at St. Anna Hospital (Ferrara, Italy), using the Spearman non-parametric correlation index. Even though significant correlations were found among the variables, the overall results showed that the main factor influencing the severity of the adverse effects was the dosage of cisplatin administered.

View Figures

View References

1	Blanchard EM: Cisplatin and solid tumours: still working, after all these years. J Solid Tumors. 2:26–33. 2012.
2	Chaudhary UB and Haldas JR: Long-term complications of chemotherapy for germ cell tumours. Drugs. 63:1565–1577. 2003. View Article : Google Scholar : PubMed/NCBI
3	Tewari KS and Monk BJ: Gynecologic Oncology Group trials of chemotherapy for metastatic and recurrent cervical cancer. Curr Oncol Rep. 7:419–434. 2005. View Article : Google Scholar : PubMed/NCBI
4	Armstrong DK, Bookman MA, McGuire W, Bristow RE, Schilder JM and Group GO: A phase I study of paclitaxel, topotecan, cisplatin and filgrastim in patients with newly diagnosed advanced ovarian epithelial malignancies: a Gynecologic Oncology Group study. Gynecol Oncol. 105:667–671. 2007. View Article : Google Scholar
5	Ridwelski K, Gebauer T, Fahlke J, et al: Combination chemotherapy with docetaxel and cisplatin for locally advanced and metastatic gastric cancer. Ann Oncol. 12:47–51. 2001. View Article : Google Scholar : PubMed/NCBI
6	Lee KW, Kim JH, Yun T, et al: Phase II study of low-dose paclitaxel and cisplatin as a second-line therapy after 5-fluorouracil/platinum chemotherapy in gastric cancer. J Korean Med Sci. 22(Suppl): S115–S121. 2007. View Article : Google Scholar : PubMed/NCBI
7	Cullen KJ, Yang Z, Schumaker L and Guo Z: Mitochondria as a critical target of the chemotheraputic agent cisplatin in head and neck cancer. J Bioenerg Biomembr. 39:43–50. 2007. View Article : Google Scholar : PubMed/NCBI
8	Vokes EE: Induction chemotherapy for head and neck cancer: recent data. Oncologist. 15(Suppl 3): 3–7. 2010. View Article : Google Scholar : PubMed/NCBI
9	Niell HB, Herndon JE, Miller AA, et al: Randomized phase III intergroup trial of etoposide and cisplatin with or without paclitaxel and granulocyte colony-stimulating factor in patients with extensive-stage small-cell lung cancer: Cancer and Leukemia Group B Trial 9732. J Clin Oncol. 23:3752–3759. 2005. View Article : Google Scholar
10	Bosch ME, Sánchez AJ, Rojas FS and Ojeda CB: Analytical methodologies for the determination of cisplatin. J Pharm Biomed Anal. 47:451–459. 2008. View Article : Google Scholar : PubMed/NCBI
11	Hohnloser JH, Schierl R, Hasford B and Emmerich B: Cisplatin based chemotherapy in testicular cancer patients: long term platinum excretion and clinical effects. Eur J Med Res. 1:509–514. 1996.PubMed/NCBI
12	Gietema JA, Meinardi MT, Messerschmidt J, et al: Circulating plasma platinum more than 10 years after cisplatin treatment for testicular cancer. Lancet. 355:1075–1076. 2000.PubMed/NCBI
13	Brouwers EE, Huitema AD, Beijnen JH and Schellens JH: Long-term platinum retention after treatment with cisplatin and oxaliplatin. BMC Clin Pharmacol. 8:72008. View Article : Google Scholar : PubMed/NCBI
14	Tothill P, Klys HS, Matheson LM, McKay K and Smyth JF: The long-term retention of platinum in human tissues following the administration of cisplatin or carboplatin for cancer chemotherapy. Eur J Cancer. 28A:1358–1361. 1992. View Article : Google Scholar : PubMed/NCBI
15	Gerl A and Schierl R: Urinary excretion of platinum in chemotherapy-treated long-term survivors of testicular cancer. Acta Oncol. 39:519–522. 2000. View Article : Google Scholar : PubMed/NCBI
16	Gregg RW, Molepo JM, Monpetit VJ, et al: Cisplatin neurotoxicity: the relationship between dosage, time, and platinum concentration in neurologic tissues, and morphologic evidence of toxicity. J Clin Oncol. 10:795–803. 1992.PubMed/NCBI
17	DeConti RC, Toftness BR, Lange RC and Creasey WA: Clinical and pharmacological studies with cis-diamminedichloroplatinum (II). Cancer Res. 33:1310–1315. 1973.PubMed/NCBI
18	Go RS and Adjei AA: Review of the comparative pharmacology and clinical activity of cisplatin and carboplatin. J Clin Oncol. 17:409–422. 1999.PubMed/NCBI
19	Schweitzer VG: Cisplatin-induced ototoxicity: the effect of pigmentation and inhibitory agents. Laryngoscope. 103:1–52. 1993. View Article : Google Scholar : PubMed/NCBI
20	Lautermann J, Song B, McLaren J and Schacht J: Diet is a risk factor in cisplatin ototoxicity. Hear Res. 88:47–53. 1995. View Article : Google Scholar : PubMed/NCBI
21	Tanaka F, Whitworth CA and Rybak LP: Influence of pH on the ototoxicity of cisplatin: a round window application study. Hear Res. 177:21–31. 2003. View Article : Google Scholar : PubMed/NCBI
22	Bertolaso L, Martini A, Bindini D, et al: Apoptosis in the OC-k3 immortalized cell line treated with different agents. Audiology. 40:327–335. 2001. View Article : Google Scholar : PubMed/NCBI
23	Hyppolito MA, de Oliveira JA and Rossato M: Cisplatin ototoxicity and otoprotection with sodium salicylate. Eur Arch Otorhinolaryngol. 263:798–803. 2006. View Article : Google Scholar : PubMed/NCBI
24	Previati M, Lanzoni I, Corbacella E, et al: RNA expression induced by cisplatin in an organ of Corti-derived immortalized cell line. Hear Res. 196:8–18. 2004. View Article : Google Scholar : PubMed/NCBI
25	Arafa HM, Abdel-Hamid MA, El-Khouly AA, Elmazar MM and Osman AM: Enhancement by dexamethasone of the therapeutic benefits of cisplatin via regulation of tumor angiogenesis and cell cycle kinetics in a murine tumor paradigm. Toxicology. 222:103–113. 2006. View Article : Google Scholar : PubMed/NCBI
26	Drottar M, Liberman MC, Ratan RR and Roberson DW: The histone deacetylase inhibitor sodium butyrate protects against cisplatin-induced hearing loss in guinea pigs. Laryngoscope. 116:292–296. 2006. View Article : Google Scholar : PubMed/NCBI
27	Hatzopoulos S, Di Stefano M, Albertin A and Martini A: Evaluation of cisplatin ototoxicity in a rat animal model. Ann NY Acad Sci. 884:211–225. 1999. View Article : Google Scholar : PubMed/NCBI
28	Kartalou M and Essigmann JM: Mechanisms of resistance to cisplatin. Mutat Res. 478:23–43. 2001. View Article : Google Scholar : PubMed/NCBI
29	Previati M, Lanzoni I, Astolfi L, et al: Cisplatin cytotoxicity in organ of Corti-derived immortalized cells. J Cell Biochem. 101:1185–1197. 2007. View Article : Google Scholar : PubMed/NCBI
30	Previati M, Lanzoni I, Corbacella E, et al: Cisplatin-induced apoptosis in human promyelocytic leukemia cells. Int J Mol Med. 18:511–516. 2006.PubMed/NCBI
31	Rabik CA and Dolan ME: Molecular mechanisms of resistance and toxicity associated with platinating agents. Cancer Treat Rev. 33:9–23. 2007. View Article : Google Scholar : PubMed/NCBI
32	Timmer-Bosscha H, Mulder NH and de Vries EG: Modulation of cis-diamminedichloroplatinum(II) resistance: a review. Br J Cancer. 66:227–238. 1992. View Article : Google Scholar : PubMed/NCBI
33	Gosland M, Lum B, Schimmelpfennig J, Baker J and Doukas M: Insights into mechanisms of cisplatin resistance and potential for its clinical reversal. Pharmacotherapy. 16:16–39. 1996.PubMed/NCBI
34	Adjei AA, Budihardjo II, Rowinsky EK, et al: Cytotoxic synergy between pyrazoloacridine (NSC 366140) and cisplatin in vitro: inhibition of platinum-DNA adduct removal. Clin Cancer Res. 3:761–770. 1997.PubMed/NCBI
35	Rybak LP and Whitworth CA: Ototoxicity: therapeutic opportunities. Drug Discov Today. 10:1313–1321. 2005. View Article : Google Scholar : PubMed/NCBI
36	van den Berg JH, Beijnen JH, Balm AJ and Schellens JH: Future opportunities in preventing cisplatin induced ototoxicity. Cancer Treat Rev. 32:390–397. 2006.PubMed/NCBI
37	Daldal A, Odabasi O and Serbetcioglu B: The protective effect of intratympanic dexamethasone on cisplatin-induced ototoxicity in guinea pigs. Otolaryngol Head Neck Surg. 137:747–752. 2007. View Article : Google Scholar : PubMed/NCBI
38	Astolfi L, Simoni E, Ciorba A and Martini A: In vitro protective effects of Ginkgo biloba against cisplatin toxicity in mouse cell line OCk3. Audiol Med. 6:251–258. 2008. View Article : Google Scholar
39	Chen WC, Jackson A, Budnick AS, et al: Sensorineural hearing loss in combined modality treatment of nasopharyngeal carcinoma. Cancer. 106:820–829. 2006. View Article : Google Scholar : PubMed/NCBI
40	Rademaker-Lakhai JM, Crul M, Pluim D, et al: Phase I clinical and pharmacologic study of a 2-weekly administration of cisplatin and gemcitabine in patients with advanced non-small cell lung cancer. Anticancer Drugs. 16:1029–1036. 2005. View Article : Google Scholar : PubMed/NCBI
41	Rivera F, Vega-Villegas ME, López-Brea MF, et al: Long term results of a phase II trial of induction chemotherapy with uracil-ftegafur (UFT), vinorelbine and cisplatin (UFTVP) followed by radiotherapy concomitant with UFT and carboplatin (RT/UFTJ) in non-resectable locally advanced (stage IV-B) squamous cell head and neck carcinoma and peripheral blood stem cell support (PBSCS) with febrile neutropenia. Clin Transl Oncol. 9:40–47. 2007.
42	Uhm JE, Lim HY, Kim WS, et al: Paclitaxel with cisplatin as salvage treatment for patients with previously treated advanced transitional cell carcinoma of the urothelial tract. Neoplasia. 9:18–22. 2007. View Article : Google Scholar : PubMed/NCBI
43	Zuur CL, Simis YJ, Verkaik RS, et al: Hearing loss due to concurrent daily low-dose cisplatin chemoradiation for locally advanced head and neck cancer. Radiother Oncol. 89:38–43. 2008. View Article : Google Scholar : PubMed/NCBI
44	Regione Emilia-Romagna certified (Internet). Reportistica predefinita REM anno. 2006, (updated 2007 Oct 30). Available from: http://www.regione.emilia-romagna.it/sas/rem/report_predef/2006/REM05_2.htm.
45	Kris MG, Hesketh PJ, Somerfield MR, et al: American Society of Clinical Oncology guideline for antiemetics in oncology: update 2006. J Clin Oncol. 24:2932–2947. 2006. View Article : Google Scholar : PubMed/NCBI
46	Atallah E and Flaherty L: Treatment of metastatic malignant melanoma. Curr Treat Options Oncol. 6:185–193. 2005. View Article : Google Scholar
47	von der Maase H: Current and future perspectives in advanced bladder cancer: is there a new standard? Semin Oncol. 29:3–14. 2002.PubMed/NCBI
48	Tiseo M and Ardizzoni A: Chemotherapy in the treatment of thymic tumours. Oncol Rev. 2:95–101. 2008. View Article : Google Scholar
49	Girard N, Mornex F, Van Houtte P, Cordier JF and van Schil P: Thymoma: a focus on current therapeutic management. J Thorac Oncol. 4:119–126. 2009. View Article : Google Scholar : PubMed/NCBI
50	National Cancer Institute. Gastrointestinal Complications PDQ^®. 2012, National Cancer Institute; Bethesda, MD: (Updated 07/18/2012). Available from: http://cancer.gov/cancertopics/pdq/supportivecare/gastrointestinalcomplications/HealthProfessional.